← Oncology Approval Tracker

FDA DECISION ·

Ryzneuta

efbemalenograstim alfa-vuxw · Evive Biotechnology

FDA approvalNew therapyChemotherapy-associated neutropenia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

To lower infection risk manifested by febrile neutropenia in adults with nonmyeloid malignancies receiving myelosuppressive cancer treatment with a clinically significant risk of febrile neutropenia.

LAMPGEN ANALYSIS

Why it matters

The approval added a long-acting G-CSF option for chemotherapy supportive care.

What research teams should watch

Document the chemotherapy regimen's febrile-neutropenia risk and coordinate post-chemotherapy administration.

PRIMARY RECORDS

Sources